Oncternal Therapeutics, Inc.
Business
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapies for cancers with high unmet medical need. It develops small molecule DAARIs (lead ONCT-534), ROR1-targeting therapies including an autologous CAR T cell product (ONCT-808), and the monoclonal antibody zilovertamab. Key business segments include its DAARI program, ROR1 CAR T program and antibody programs, supported by in‑licensing and research collaborations. Its products advance through multi-center clinical trials, third‑party contract manufacturing, and regional licensing arrangements for territories such as Greater China.
Summary from filing dated 2024-03-07
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|---|---|---|
| Grant revenue | 785,000 | 1 | 4 | 3 | 2 | |
| Research and development | 30 | 33 | 24 | 13 | 10 | |
| General and administrative | 13 | 13 | 12 | 8 | 7 | |
| Total operating expenses | 42 | 46 | 36 | 21 | 36 | |
| Loss from operations | −42 | −45 | −31 | −18 | −33 | |
| Interest income | 2 | 777,000 | 33,000 | 16,000 | 188,000 | |
| Net loss | −39 | −44 | −31 | −17 | −34 | |
| Unrealized gain (loss) on available-for-sale securities, net | −6,000 | 9,000 | — | — | — | |
| Comprehensive loss | −39 | −44 | −31 | — | — | |
| Net loss per share, basic | −13.43 | −16.8 | −0.64 | — | — | |
| Net loss per share, diluted | −13.43 | −16.8 | −0.64 | — | — | |
| Weighted-average shares outstanding, basic | 3 | 3 | 49 | — | — | |
| Weighted-average shares outstanding, diluted | 3 | 3 | 49 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 37 | 91 | 117 | 20 | |
| Short-term investments | 28 | 27 | 0 | — | — | |
| Prepaid and other | 2 | 4 | 2 | 1 | 736,000 | |
| Total current assets | 36 | 67 | 93 | 118 | 21 | |
| Right-of-use asset | 258,000 | 87,000 | 75,000 | 40,000 | 190,000 | |
| Other assets | 412,000 | 1 | 657,000 | 766,000 | 767,000 | |
| Total assets | 37 | 69 | 94 | 119 | 22 | |
| Accounts payable | 1 | 3 | 2 | 1 | 871,000 | |
| Accrued liabilities | 4 | 5 | 3 | 3 | 3 | |
| Lease, current | 173,000 | 87,000 | 75,000 | 40,000 | 99,000 | |
| Total current liabilities | 5 | 8 | 5 | 6 | 7 | |
| Deferred compensation | 1 | 0 | — | — | — | |
| Lease, net of current | 145,000 | 0 | — | — | 91,000 | |
| Total liabilities | 7 | 8 | — | — | — | |
| Commitments and contingencies (Note 4) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, authorized shares 5,000 at December 31, 2023 and 2022; issued and outstanding shares none | 0 | 0 | 0 | — | — | |
| Common stock, $0.001 par value; authorized shares - 120,000 at December 31, 2023 and 60,000 at 2022; issued and outstanding shares - 2,948 and 2,829 at December 31, 2023 and 2022, respectively | 3,000 | 3,000 | 49,000 | 49,000 | 15,000 | |
| Additional paid-in capital | 228 | 219 | 202 | 196 | 80 | |
| Accumulated other comprehensive income | 3,000 | 9,000 | 0 | — | — | |
| Accumulated deficit | −198 | −158 | −114 | −83 | −66 | |
| Total stockholders equity | 30 | 61 | 88 | 113 | 14 | |
| Total liabilities and stockholders equity | 37 | 69 | 94 | 119 | 22 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −39 | −44 | −31 | −17 | −34 | |
| Stock-based compensation | 8 | 7 | 6 | 2 | 507,000 | |
| Accretion of discounts on short-term investments | −2 | −75,000 | 0 | — | — | |
| Noncash lease expense | 174,000 | 179,000 | 169,000 | 150,000 | 92,000 | |
| Prepaid and other assets | 3 | −2 | −713,000 | −529,000 | −44,000 | |
| Accounts payable | −2 | 958,000 | 816,000 | 272,000 | −5 | |
| Accrued liabilities | −801,000 | 1 | 399,000 | 739,000 | −1 | |
| Deferred compensation | 1 | 0 | — | — | — | |
| Change in lease liability | −114,000 | −179,000 | −169,000 | −150,000 | −92,000 | |
| Net cash used in operating activities | −32 | −37 | −27 | −17 | −17 | |
| Purchases of available-for-sale securities | −64 | −26 | 0 | — | — | |
| Maturities of available-for-sale securities | 65 | 0 | — | — | — | |
| Net cash provided by investing activities | 651,000 | −26 | 0 | — | 16 | |
| Proceeds from the issuance of common stock, net | 1 | 10 | 0 | 114 | — | |
| Repurchases of common stock for tax withholding obligations | −156,000 | −3,000 | 0 | — | — | |
| Net cash provided by financing activities | 1 | 10 | 617,000 | 114 | 15,000 | |
| Net decrease in cash and cash equivalents | −30 | −54 | −26 | 97 | −594,000 | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 345,000 | 191,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Oncternal Therapeutics, Inc.'s CIK number?
Oncternal Therapeutics, Inc.'s SEC CIK number is 0001260990 (1260990). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Oncternal Therapeutics, Inc.'s SEC filings?
All of Oncternal Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.